NCT06827288 Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder
| NCT ID | NCT06827288 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RAND |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-10-04 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2024-10-04 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The ADAPT-ED study is a two-stage, sequential multiple assignment randomized trial (SMART) to inform the development of an adaptive intervention that is optimally effective in increasing long-term buprenorphine use for adults presenting to the ED with probable opioid use disorder (OUD).
Eligibility Criteria
Inclusion Criteria: * Presented for ED care at ARMC * Age 18 or older * Probable OUD diagnosis * Speak and understand English or Spanish * Have capacity to give informed consent * Provide a signed and dated informed consent form
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06827288 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06827288 currently recruiting?
Yes, NCT06827288 is actively recruiting participants. Contact the research team at mariahk@rand.org for enrollment information.
Where is the NCT06827288 trial being conducted?
This trial is being conducted at Colton, United States.
Who is sponsoring the NCT06827288 clinical trial?
NCT06827288 is sponsored by RAND. The trial plans to enroll 500 participants.